MX2022005238A - Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida. - Google Patents

Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.

Info

Publication number
MX2022005238A
MX2022005238A MX2022005238A MX2022005238A MX2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A MX 2022005238 A MX2022005238 A MX 2022005238A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
lenalidomide
hla
bispecific antibody
Prior art date
Application number
MX2022005238A
Other languages
English (en)
Inventor
Christian Klein
Christian Augsberger
Sabine Marion Subklewe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022005238A publication Critical patent/MX2022005238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La presente invención se refiere al tratamiento del cáncer, en particular, al tratamiento del cáncer usando un anticuerpo biespecífico contra HLA-A2/WT1 X CD3 y lenalidomida.
MX2022005238A 2019-11-05 2020-11-03 Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida. MX2022005238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207090 2019-11-05
PCT/EP2020/080763 WO2021089513A1 (en) 2019-11-05 2020-11-03 Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide

Publications (1)

Publication Number Publication Date
MX2022005238A true MX2022005238A (es) 2022-06-08

Family

ID=68468600

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005238A MX2022005238A (es) 2019-11-05 2020-11-03 Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.

Country Status (12)

Country Link
US (1) US20220275093A1 (es)
EP (1) EP4054716A1 (es)
JP (1) JP2023501276A (es)
KR (1) KR20220093323A (es)
CN (1) CN115003384A (es)
AU (1) AU2020381349A1 (es)
BR (1) BR112022008652A2 (es)
CA (1) CA3155308A1 (es)
IL (1) IL292103A (es)
MX (1) MX2022005238A (es)
TW (1) TW202132341A (es)
WO (1) WO2021089513A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023073225A1 (en) * 2021-11-01 2023-05-04 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and a 4-1bb (cd137) agonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
BR112019008426A2 (pt) * 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
TWI805665B (zh) 2017-12-21 2023-06-21 瑞士商赫孚孟拉羅股份公司 結合hla-a2/wt1之抗體

Also Published As

Publication number Publication date
BR112022008652A2 (pt) 2022-07-19
AU2020381349A1 (en) 2022-04-28
US20220275093A1 (en) 2022-09-01
WO2021089513A1 (en) 2021-05-14
TW202132341A (zh) 2021-09-01
CA3155308A1 (en) 2021-05-14
KR20220093323A (ko) 2022-07-05
CN115003384A (zh) 2022-09-02
IL292103A (en) 2022-06-01
JP2023501276A (ja) 2023-01-18
EP4054716A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
EA202190365A1 (ru) Способы изготовления пакетов-мессенджеров растений
PH12019502283A1 (en) Anti-lag3 antibodies
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12020552232A1 (en) IL-11 Antibodies
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MD3328888T2 (ro) Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12020552229A1 (en) Il-11ra antibodies
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
NZ757915A (en) Anti-par2 antibodies and uses thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
MX2022005238A (es) Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp